Clinical trial · Interventional
Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells
Pilot Study of Anti-GD2 and Expanded, Activated Natural Killer Cell Infusion for Neuroblastoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Neuroblastoma is a neoplasm of the sympathetic nervous system which affects mostly children younger than 5 years of age. It is a heterogeneous disease, with nearly 50% of patients presenting with a high-risk phenotype. After standard treatment, the 2-year event-free survival (EFS) for high risk neuroblastoma (EFS) is only about 50%. Immunotherapy with anti-GD2 antibodies has been shown to improve EFS in Children's Oncology Group and SIOPEN trials. The anti-GD2 antibody mediates neuroblastoma cell killing primarily through antibody-dependent cell-mediated cytotoxicity (ADCC). Natural killer (NK) cells are the main effectors of ADCC. We postulate that infusion of expanded activated NK cells from healthy haploidentical donors along with anti-GD2 antibody will enhance neuroblastoma killing.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroblastoma Recurrent | Neuroblastoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anti-GD2 in combination with NK cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Anti-GD2 in combination with NK cells
- description
- This is a single arm study. Patients with high risk neuroblastoma who have residual measurable disease will receive a combination of 5 days of anti-GD2 with expanded activated NK cells.
- interventionNames
- Biological: Anti-GD2 in combination with NK cells
Primary outcomes (1)
- measure
- To measure tumor response after infusion of expanded activated haploidentical NK cells with anti-GD2. Response will be assessed as defined by Revised International Neuroblastoma Response Criteria 2017.
- timeFrame
- 2 years
- description
- Disease status at primary and metastatic soft tissue sites will be assessed using MIBG scans or PET scan as applicable. RECIST and Curie scoring systems will be used to assess response. Metastatic bone disease will be assessed using MIBG or PET scan. Bone marrow will be assessed by histology or flow cytometry. Disease response will be defined as Complete response/remission (CR), Partial response (PR), Minor response, Stable disease (SD), or Progressive disease(PD).
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 6 Months
- Maximum age
- 25 Years
Show eligibility criteria text
Inclusion Criteria: \- A) Inclusion criteria for activated NK cell Recipient: 1. Age 6 months to 25 years old. 2. Patients with high risk or relapsed neuroblastoma who have measurable residual disease (based on imaging findings with Curie scoring or MIBG or PET imaging criteria) after receiving or has refused to receive standard therapy. 1. High risk will be defined as stage IV disease with poor response to chemotherapy. Residual disease after surgery or prior to autologous stem cell rescue which is part of Standard of Care. Infants with nMYC amplification will not automatically qualify for the protocol unless they have residual disease after surgery. 2. Recurrence after completion of standard treatment. 3. Shortening fraction greater than or equal to 25% or Left ventricular ejection fraction (LVEF) greater than or equal to 40%. 4. Glomerular filtration rate greater than or equal to 60 ml/min/1.73 m2. 5. Pulse oximetry greater than or equal to 92% on room air. 6. Direct bilirubin less than or equal to 3.0 mg/dL (50 mmol/L). 7. Alanine aminotransferase (ALT) is no more than 2 times the upper limit of normal. 8. Aspartate transaminases (AST) is no more than 2 times the upper limit of normal. 9. Karnofsky or Lansky performance score of greater than or equal to 50. 10. Does not have a current pleural or pericardial effusion. 11. Has a suitable adult family member donor available for NK cell donation. 12. Has recovered from all acute NCI Common Terminology Criteria for Adverse Events (CTCAE) grade II-IV non-hematologic acute toxicities resulting from prior therapy per the judgment of the PI. 13. At least two weeks since receipt of any biological therapy, systemic chemotherapy, and/or radiation therapy. 14. Is not receiving more than the equivalent of prednisone 10 mg daily. 15. Not pregnant (negative serum or urine pregnancy test to be conducted within 7 days prior to enrollment). 16. Not lactating. B) Inclusion criteria for NK cell Donor: 1. First and second degree relative acceptable. 2. 18 years of age or above. 3. Not lactating. 4. Greater than or equal to 3 of 6 HLA match to recipient. 5. .Meets eligibility and suitability criteria for hematopoietic cells donation as per institutional guidelines. 6. Not pregnant (negative serum or urine pregnancy test to be conducted within 7 days prior to enrollment). Exclusion Criteria: * Failure to meet any of the above criteria
References
Publications (3)
- BACKGROUNDYu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010 Sep 30;363(14):1324-34. doi: 10.1056/NEJMoa0911123. PMID 20879881
- BACKGROUNDCho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res. 2010 Aug 1;16(15):3901-9. doi: 10.1158/1078-0432.CCR-10-0735. Epub 2010 Jun 11. PMID 20542985
- BACKGROUNDTarek N, Le Luduec JB, Gallagher MM, Zheng J, Venstrom JM, Chamberlain E, Modak S, Heller G, Dupont B, Cheung NK, Hsu KC. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest. 2012 Sep;122(9):3260-70. doi: 10.1172/JCI62749. Epub 2012 Aug 6. PMID 22863621